ECM
CNTA

ExodusPoint Capital Management’s Centessa Pharmaceuticals CNTA Stock Holding History

ExodusPoint Capital Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-87,210
Closed -$788K – 1680
2024
Q2 		$788K Sell
87,210
-292,104
-77% -$2.77M 0.01% 1098
2024
Q1 		$4.29M Buy
379,314
+82,428
+28% +$781K 0.03% 444
2023
Q4 		$2.36M Buy
+296,886
New +$1.99M 0.02% 534

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

ExodusPoint Capital Management's CNTA Position: Q3 2024 in Review

ExodusPoint Capital Management sold out of Centessa Pharmaceuticals (CNTA) in Q3 2024, closing a stake of 87,210 shares — an estimated $788K sold.

ExodusPoint Capital Management first reported a position in CNTA in Q4 2023 and held it in 3 quarters. The position peaked at $4.29M in Q1 2024. 103 funds tracked by Wall St. Rank hold CNTA as of Q3 2024.

  • ExodusPoint Capital Management reported no remaining Centessa Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • ExodusPoint Capital Management sold 87,210 Centessa Pharmaceuticals shares in Q3 2024, an estimated $788K.
  • ExodusPoint Capital Management first reported a position in Centessa Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • ExodusPoint Capital Management's Centessa Pharmaceuticals position peaked at $4.29M in Q1 2024.
  • 103 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q3 2024.

Based on ExodusPoint Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.